May Garrett

1.0k total citations
23 papers, 665 citations indexed

About

May Garrett is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, May Garrett has authored 23 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 8 papers in Hematology. Recurrent topics in May Garrett's work include Renal cell carcinoma treatment (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Lung Cancer Treatments and Mutations (6 papers). May Garrett is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Lung Cancer Treatments and Mutations (6 papers). May Garrett collaborates with scholars based in United States, United Kingdom and Georgia. May Garrett's co-authors include Yazdi K. Pithavala, Karen J. Klamerus, Brian Hee, Michael A. Tortorici, Melvin Toh, Ying Chen, Janice P. Dutcher, Walter M. Stadler, Brian I. Rini and Robert J. Motzer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

May Garrett

22 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
May Garrett United States	14	376	316	266	153	113	23	665
M.S. Gordon United States	14	219 0.6×	309 1.0×	212 0.8×	109 0.7×	212 1.9×	89	686
Sachin Shah United States	13	172 0.5×	211 0.7×	286 1.1×	57 0.4×	103 0.9×	25	737
Anusha Vakiti United States	9	566 1.5×	445 1.4×	301 1.1×	183 1.2×	162 1.4×	27	1.0k
Yasuhito Fujisaka Japan	17	272 0.7×	247 0.8×	481 1.8×	83 0.5×	78 0.7×	51	885
R. Sridhara United States	15	234 0.6×	198 0.6×	375 1.4×	179 1.2×	87 0.8×	24	862
Elmer Berghorn United States	13	418 1.1×	438 1.4×	1.1k 4.3×	159 1.0×	117 1.0×	20	1.5k
Jennifer Arrondeau France	20	522 1.4×	317 1.0×	838 3.2×	164 1.1×	57 0.5×	74	1.3k
Sander Bins Netherlands	17	324 0.9×	376 1.2×	688 2.6×	117 0.8×	86 0.8×	59	1.2k
Rossana Roncato Italy	18	159 0.4×	284 0.9×	395 1.5×	144 0.9×	46 0.4×	52	907
Marina D. Kaymakcalan United States	15	374 1.0×	261 0.8×	423 1.6×	217 1.4×	35 0.3×	32	912

Countries citing papers authored by May Garrett

Since Specialization

Citations

This map shows the geographic impact of May Garrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by May Garrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites May Garrett more than expected).

Fields of papers citing papers by May Garrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by May Garrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by May Garrett. The network helps show where May Garrett may publish in the future.

Co-authorship network of co-authors of May Garrett

This figure shows the co-authorship network connecting the top 25 collaborators of May Garrett. A scholar is included among the top collaborators of May Garrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with May Garrett. May Garrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeAngelo, Daniel J., Ryan D. Cassaday, Derek Z. Yang, et al.. (2024). Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 732–732. 1 indexed citations

Garrett, May, et al.. (2023). Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Medicine. 12(17). 17981–17992. 5 indexed citations

Garrett, May, Ana Ruiz-Garcı́a, Kourosh Parivar, Brian Hee, & Joseph Boni. (2019). Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. Journal of Pharmacokinetics and Pharmacodynamics. 46(3). 211–222. 26 indexed citations

Garrett, May, et al.. (2017). Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia. Blood. 130. 2899–2899. 6 indexed citations

Chen, Ying, Michael A. Tortorici, May Garrett, et al.. (2015). Axitinib plasma pharmacokinetics and ethnic differences. Investigational New Drugs. 33(2). 521–532. 23 indexed citations

Chen, Ying, Brian I. Rini, Robert J. Motzer, et al.. (2015). Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted Oncology. 11(2). 229–234. 17 indexed citations

Tortorici, Michael A., Ezra E.W. Cohen, Yazdi K. Pithavala, et al.. (2014). Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemotherapy and Pharmacology. 74(6). 1279–1289. 13 indexed citations

Rini, Brian I., May Garrett, Bill Poland, et al.. (2013). Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. The Journal of Clinical Pharmacology. 53(5). 491–504. 117 indexed citations

Chen, Ying, Michael A. Tortorici, May Garrett, et al.. (2013). Clinical Pharmacology of Axitinib. Clinical Pharmacokinetics. 52(9). 713–725. 99 indexed citations

10.

Garrett, May, Bill Poland, Meghan Brennan, et al.. (2013). Population pharmacokinetic analysis of axitinib in healthy volunteers. British Journal of Clinical Pharmacology. 77(3). 480–492. 21 indexed citations

11.

Pithavala, Yazdi K., Ying Chen, Melvin Toh, et al.. (2012). Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemotherapy and Pharmacology. 70(1). 103–112. 36 indexed citations

12.

Yap, Tami, Libo Yan, David Olmos, et al.. (2011). Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.. Journal of Clinical Oncology. 29(15_suppl). 3001–3001. 9 indexed citations

13.

Pusey, Charles D., et al.. (2010). Experience of using human albumin solution 4·5% in 1195 therapeutic plasma exchange procedures. Transfusion Medicine. 20(4). 244–249. 14 indexed citations

14.

Pithavala, Yazdi K., Sadayappan V. Rahavendran, May Garrett, et al.. (2010). Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Investigational New Drugs. 30(1). 273–281. 53 indexed citations

15.

Bello, Carlo L., May Garrett, Laurie Sherman, et al.. (2010). Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemotherapy and Pharmacology. 66(4). 699–707. 31 indexed citations

16.

Khosravan, Reza, Melvin Toh, May Garrett, et al.. (2009). Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function. The Journal of Clinical Pharmacology. 50(4). 472–481. 60 indexed citations

17.

Pithavala, Yazdi K., et al.. (2009). Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemotherapy and Pharmacology. 65(3). 563–570. 66 indexed citations

18.

Pithavala, Yazdi K., Melvin Toh, May Garrett, et al.. (2008). Effect of food on the pharmacokinetics of Axitinib (AG-013736) in healthy volunteers. Cancer Research. 68. 233–233. 3 indexed citations

19.

Bello, Carlo L., Hai‐Zhi Bu, Shem Patyna, et al.. (2007). A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects. Cancer Research. 67. 6 indexed citations

20.

Tran, Jonathan Q., et al.. (2003). Significant Interactions between CYP Probes in A 6‐Drug Cocktail. Clinical Pharmacology & Therapeutics. 73(2).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact